Tenaya Therapeutics Lands $1.13B Alnylam Deal to Fuel Heart Disease Research

Tenaya Therapeutics announced on Thursday that it has entered into a research collaboration agreement with Alnylam Pharmaceuticals. This partnership could be valued at up to $1.13 billion and aims to advance the development of new therapies for various heart conditions.

According to Ranked Stocks' proprietary rating system, Alnylam Pharmaceuticals (ALNY) currently holds an RS Score of 54.93, placing it in the 15.16th percentile within its country and the 11.29th percentile within its sector. Analysis of ALNY's underlying metrics indicates weaker performance across several key sections, including Valuation (55.07), Growth (37.67), Profitability (43.17), Momentum (24.35), and EPS Revisions (70.00). Want to discover which stocks rank the highest? Start your free 7-day trial at rankedstocks.com.